Summary
RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company's product candidates include RCT-01 for the treatment of chronic tendinosis; RCS-01 to treat aging and sun damaged skin; and RCH-01 for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. for establishing a clinical research program to develop and commercialize RCS-01 and RCT-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. It also has a collaboration research project agreement with the University of British Columbia to build a hair follicle cell data map. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.
History
RepliCel was founded in 2011 by Dr. Rman Hextall and Dr. Kevin McElwee. Their product portfolio consists of proprietary cell populations derived from autologous (the patient’s own) tissue, extracted non-invasively and concentrated using the company’s proprietary methods. RepliCel's lead product is RCT-01 which addresses progressive hair loss affecting millions of men and women worldwide.
Mission
RepliCel is committed to developing cell therapy-based treatments to address unmet medical needs and improve the quality of life for patients. The company is focused on establishing a portfolio of products that improves full-thickness tissue repair and regeneration.
Vision
RepliCel's vision is to become a leader in the field of cell therapy and to establish our products as the go-to solution for those seeking dermatological care and aesthetics.
Key Team
Dr. Rolf Hoffmann M.D. (Chief Medical Officer & Member of Clinical Advisory Board)
Mr. R. Lee Buckler B.Ed., L.L.B., LLB (Corp. Sec. & Director)
Ben Austring (Chief Legal Officer & Operations Mang.)
Mr. Darrell Panich M.Sc, PMP, CPM (Clinical Consultant)
Recognition and Awards
RepliCel has received numerous awards, including the Emerging Technology Award from the American Society of Dermatology, the Global Entrepreneur of the Year Award from the British Columbia Technology Industry Association, and the Dow-Hohm Prize for Excellence in Health Innovation.
References
